Observational study · people
LL-37 blood levels highest in adults with lung tuberculosis
Checked against the paper Observational studyPublished by PepVault
The takeaway
Natural LL-37 levels in the blood run higher during lung infections, most of all in TB; this is a measurement study, not a test of LL-37 as a treatment.
- Kind
- Observational study
- Studied in
- People
- Published
- 2017
- Journal
- Clin Invest Med
What they tested
The team wanted to know how blood levels of the body's own LL-37 differ between adults with lung tuberculosis, adults with bacterial pneumonia, and healthy people.
How the study was done
An observational comparison of 30 adults with lung tuberculosis (TB), 30 with pneumonia from Gram-positive bacteria, 30 with pneumonia from Gram-negative bacteria, and 30 healthy controls. LL-37 in serum (the liquid part of blood) was measured with ELISA, a lab test that detects a specific protein.

What they found
People with TB had an average serum LL-37 of 13.94±5.13 ng/mL (mean ± SEM, a measure of how precise the average is). That was significantly higher than in Gram-positive pneumonia (7.87±4.58 ng/mL, P=0.00077), in Gram-negative pneumonia (10.27±3.60 ng/mL, P=0.00730), and in healthy controls (1.75±0.71 ng/mL, P=0.00004). The authors read this as a sign that LL-37 is an important part of the body's defense in bacterial lung infections, especially when the germ lives inside cells.
What it doesn’t show
This was a measurement study of the body's own LL-37 in blood, with no treatment arm, so it tells us nothing about the effects of taking the peptide. The groups were small at 30 each, and a link between higher levels and infection is not proof that LL-37 caused any benefit.
The paper
Majewski et al. Circulating cathelicidin LL-37 in adult patients with pulmonary infectious diseases. Clin Invest Med. 2017.
The compound
More studies on LL-37
- LL-37 cream: bigger granulation gains in diabetic foot ulcersRandomized trial · people · 2023
- LL-37 taken by mouth shortened time to negative COVID-19 RNA testRandomized trial · people · 2023
- LL-37: no healing gain over placebo for venous leg ulcers overallRandomized trial · people · 2021
- LL-37 drove IL-1β and IL-18 release from human and murine macrophagesCell study · human and murine macrophages · 2013
- LL-37 raised TLR9 and interferon output in human skin cellsCell study · normal human keratinocytes · 2012
- Every study on LL-37
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.